A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer

被引：0
|
作者：
Ozge Gumusay
Laura A. Huppert
Mark Jesus M. Magbanua
Chiara A. Wabl
Michael Assefa
Amy Jo Chien
Michelle E. Melisko
Melanie C. Majure
Mark Moasser
John Park
Hope S. Rugo
机构：
[1] Acibadem University,Department of Medical Oncology, School of Medicine
[2] University of California San Francisco,Department of Laboratory Medicine
[3] Helen Diller Family Comprehensive Cancer Center,undefined
[4] UCSF,undefined
来源：
Breast Cancer Research and Treatment | 2024年 / 203卷
关键词：
Eribulin; Cyclophosphamide; Metastatic breast cancer; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：197 / 204
页数：7
相关论文
共 50 条
  • [21] Phase II trial of Eribulin/S-1 combination therapy for advanced/recurrent breast cancer
    Iwasa, Tsutomu
    Komoike, Yoshifumi
    Tsurutani, Junji
    Nakagawa, Kazuhiko
    Mizuno, Yutaka
    Matsunami, Nobuki
    Yamamura, Jun
    Otani, Shoichiro
    Kojima, Yasuyuki
    Watanabe, Satomi
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] PHARMACOKINETICS OF ERIBULIN MESILATE IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH ADVANCED/METASTATIC CANCER: RESULTS FROM A PHASE IB DOSE-ESCALATION STUDY
    Twelves, C. J.
    Nasim, M.
    Anthoney, A.
    Cresti, N.
    Savulsky, C.
    Johnston, C.
    Reyderman, L.
    Wanders, J.
    Plummer, R.
    Evans, T. R. J.
    ANNALS OF ONCOLOGY, 2012, 23 : 129 - 129
  • [23] Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia G.
    D'Adamo, David R.
    Aktan, Gursel
    Tsai, Michaela L.
    O'Regan, Ruth M.
    Kaufman, Peter A.
    Wilks, Sharon T.
    Andreopoulou, Eleni
    Patt, Debra A.
    Yuan, Yuan
    Wang, Grace
    Savulsky, Claudio
    Xing, Dongyuan
    Kleynerman, Ella
    Karantza, Vassiliki
    Diab, Sami
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3061 - 3068
  • [24] CARBOPLATIN IN COMBINATION WITH EPIRUBICIN AND CYCLOPHOSPHAMIDE IN PATIENTS WITH ADVANCED OVARIAN-CANCER - A PHASE-II STUDY
    ANDERSSON, H
    FRIBERG, LG
    HORVATH, G
    JOHANSSON, O
    AKESSON, M
    WESTBERG, R
    ACTA ONCOLOGICA, 1995, 34 (06) : 821 - 827
  • [25] Phase Ib study of rebastinib plus antitubulin therapy with paclitaxel or eribulin in patients with metastatic breast cancer
    Anampa, Jesus D.
    Xue, Xiaonan
    Oktay, Maja
    Condeelis, John
    Sparano, Joseph A.
    CANCER RESEARCH, 2018, 78 (04)
  • [26] Phase Ib study of rebastinib plus antitubulin therapy with paclitaxel or eribulin in patients with metastatic breast cancer
    Anampa, Jesus D.
    Xue, Xiaonan
    Oktay, Maj A.
    Condeelis, John
    Sparano, Joseph A.
    CANCER RESEARCH, 2017, 77
  • [27] Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: phase II study.
    Tanaka, M.
    Tamura, K.
    Anan, K.
    Ohno, S.
    Nishimura, R.
    Yamamoto, Y.
    Masuda, N.
    Mitsuyama, S.
    CANCER RESEARCH, 2009, 69 (02) : 383S - 384S
  • [28] Phase I trial of eribulin in combination with S-1 for advanced and recurrent breast cancer patients
    Iwasa, Tsutomu
    Tsurutani, Junji
    Nishida, Satomi
    Komoike, Yoshifumi
    Nakagawa, Kazuhiko
    CANCER RESEARCH, 2015, 75
  • [29] Gene alteration in triple negative breast cancer patients in a phase I/II study of combination therapy with eribulin and olaparib
    Shimomura, A.
    Yonemori, K.
    Masuda, N.
    Aogi, K.
    Takahashi, M.
    Naito, Y.
    Shimizu, S.
    Nakamura, R.
    Hamada, A.
    Michimae, H.
    Hashimoto, J.
    Yamamoto, H.
    Shimizu, C.
    Tamura, K.
    Fujiwara, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
    Landry, Chrystal A.
    Blanter, Julia
    Ru, Meng
    Fasano, Julie
    Klein, Paula
    Shao, Theresa
    Bhardwaj, Aarti
    Tiersten, Amy
    ONCOLOGY, 2023,
12345